John Moroney, MD, specializes in the diagnosis and treatment of gynecologic cancers, with a focus on providing skilled and personalized longitudinal care. He believes that access to innovative surgical techniques and targeted medical therapies are essential in achieving optimal outcomes.
Dr. Moroney is the principal investigator (PI) at the University of Chicago for NRG Oncology, a National Cancer Institute-supported clinical trials cooperative group. He also serves as the PI for numerous other industry-sponsored clinical trials.
Loyola University Stritch School of Medicine
MD
Walter Reed National Military Medical Center
Internship
Walter Reed National Military Medical Center
Residency
MD Anderson Cancer Center
Fellowship
Blood-based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG-GY012.
Blood-based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG-GY012. Cancer. 2026 Oct 15; 132(20):e70649.
PMID: 42870635
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium. Gynecol Oncol. 2026 Aug; 211:171-177.
PMID: 42447658
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer. Gynecol Oncol. 2025 07; 198:1-8.
PMID: 40393272
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor a-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial.
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor a-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr; 26(4):503-515.
PMID: 40179908
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecol Oncol. 2025 03; 194:145-152.
PMID: 40221173
NCCN GuidelinesĀ® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
NCCN GuidelinesĀ® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 10; 22(8):512-519.
PMID: 39413835
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024 04 15; 130(8):1234-1245.
PMID: 38127487
Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer.
Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 12 07; 389(23):2162-2174.
PMID: 38055253
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecol Oncol. 2023 09; 176:16-24.
PMID: 37418832
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322.
PMID: 35900726